Epidemiology and pathophysiology of cancer-associated thrombosis
Top Cited Papers
Open Access
- 13 April 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (S1), S2-S9
- https://doi.org/10.1038/sj.bjc.6605599
Abstract
Venous thromboembolism (VTE) is a common complication in patients with malignant disease. First recognised by Bouillard in 1823 and later described by Trousseau in 1844, multiple studies have since provided considerable evidence for a clinical association between VTE and cancer. Across all cancers, the risk for VTE is elevated 7-fold; in certain malignancies, the risk for VTE may be increased up to 28-fold. Venous thromboembolism is the second leading cause of death in patients with cancer; among survivors, complications commonly include recurrent VTE and post-thrombotic syndrome, and (more rarely) chronic thromboembolic pulmonary hypertension, which are costly, and have a profound impact on the patient's quality of life. Tumour cells can activate blood coagulation through multiple mechanisms, including production of procoagulant, fibrinolytic, and proaggregating activities, release of proinflammatory and proangiogenic cytokines, and interacting directly with host vascular and blood cells (e.g., endothelial cells, leukocytes, and platelets) through adhesion molecules. Increasing evidence suggests that elements of the haemostatic system also have a direct role in eliciting or enhancing angiogenesis, cell survival, and metastasis. Despite the problem posed by VTE in the setting of cancer, it is evident that a significant number of oncologists do not recognise the link between cancer, its treatment, and thrombogenesis. On 22 May 2009, a group of UK-based physicians met in London, UK, to evaluate recent data on cancer thrombosis. This article (1 of 4) briefly reviews key data on the epidemiology and pathophysiology of VTE as a context for a discussion and consensus statement developed by meeting attendees, on the implications of this information for UK clinical practice.Keywords
This publication has 41 references indexed in Scilit:
- Tissue Factor and CancerSeminars in Thrombosis and Hemostasis, 2008
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Cancer and venous thromboembolismThe Lancet Oncology, 2005
- Tissue Factor–Factor VIIa SignalingArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinomaJournal of Thrombosis and Haemostasis, 2004
- Tissue Factor and Fibrin in Tumor AngiogenesisSeminars in Thrombosis and Hemostasis, 2004
- Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire surveyBMJ, 2003
- Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE SurveyThe Oncologist, 2003
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- Cancer and thrombosis revisitedBlood Reviews, 2001